Kwang Dong Pharmaceutical Co., Ltd.
Kwang Dong Pharmaceutical Co., Ltd., a prominent player in the pharmaceutical industry, is headquartered in South Korea (KR) and operates extensively across Asia. Founded in 1963, the company has established itself as a leader in the development and manufacturing of a diverse range of healthcare products, including over-the-counter medications, herbal remedies, and nutritional supplements. Kwang Dong is renowned for its commitment to quality and innovation, with core products that cater to various health needs, setting them apart in a competitive market. The company has achieved significant milestones, including advancements in research and development, which have solidified its market position. With a focus on enhancing health and well-being, Kwang Dong continues to make notable contributions to the pharmaceutical landscape, earning recognition for its dedication to excellence and customer satisfaction.
DitchCarbon Score
How does Kwang Dong Pharmaceutical Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kwang Dong Pharmaceutical Co., Ltd.'s score of 22 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kwang Dong Pharmaceutical Co., Ltd.'s reported carbon emissions
In 2019, Kwang Dong Pharmaceutical Co., Ltd. reported total carbon emissions of approximately 30,160,000 kg CO2e across all scopes. This includes about 1,569,000 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and approximately 28,591,000 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Notably, Scope 3 emissions, which encompass all other indirect emissions, accounted for the largest share at about 30,160,000 kg CO2e. The company has shown a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been disclosed. Historical data indicates a trend in emissions, with Scope 1 emissions decreasing from approximately 1,794,000 kg CO2e in 2017 to 1,569,000 kg CO2e in 2019, while Scope 2 emissions also saw a reduction from about 31,106,000 kg CO2e in 2017 to 28,591,000 kg CO2e in 2019. However, there is no available data on Scope 3 emissions for 2018, making it challenging to assess overall trends comprehensively. Kwang Dong Pharmaceutical's climate commitments remain somewhat vague, as no specific climate pledges or reduction targets have been outlined. The company operates within an industry context that increasingly prioritises sustainability and carbon reduction, suggesting potential future initiatives may align with these broader trends.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | |
|---|---|---|---|
| Scope 1 | 1,794,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 31,106,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kwang Dong Pharmaceutical Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
